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Abstract
Introduction: Hyperglycemia is associated with increased morbidity and mortality in critically ill patients and strict
glycemic control has become standard care for adults. Recent studies have questioned the optimal targets for such
management and reported increased rates of iatrogenic hypoglycemia in both critically ill children and adults. The
ability to provide accurate, real-time continuous glucose monitoring would improve the efficacy and safety of this
practice in critically ill patients. The aim of our study is to determine if a continuous, interstitial glucose monitor
will correlate with blood glucose values in critically ill children.
Methods: We evaluated 50 critically ill children age 6 weeks to 16 years old with a commercially available
continuous glucose monitor (CGM; Medtronic Guardian®). CGM values and standard blood glucose (BG) values
were compared. During the study, no changes in patient management were made based on CGM readings alone.
Results: Forty-seven patients had analyzable CGM data. A total of 1,555 CGM and routine BG measurements were
compared using Clarke error grid and Bland-Altman analysis. For all readings, 97.9% were within clinically
acceptable agreement. The mean absolute relative difference between CGM and BG readings was 15.3%. For the
1,555 paired CGM and BG measurements, there is a statistically significant linear relationship between CGM values
and BG (P <.0001). A high degree of clinical agreement existed in three subpopulation analyses based on age,
illness severity, and support measures. This included some of our smallest patients (that is, <12 months old), those
who required vasopressors, and those who were treated for critical illness hyperglycemia.
Conclusions: In one of the largest studies to date, in a highly vulnerable ICU population, CGM values have a
clinically acceptable correlation with the BG values now used diagnostically and therapeutically. Our data contest
the theoretical concerns posed by some regarding CGM use in the ICU. The existing medical evidence may now
support a role for CGM devices in the identification and management of hyperglycemia in diverse ICU settings.
Introduction
Hyperglycemia is a risk factor for morbidity and mortal-
ity in critical illness. Active glycemic control with insulin
can improve outcomes. This has been demonstrated in a
variety of adult settings and recently in a mixed medical/
surgical pediatric intensive care unit (ICU) [1-4]. The
most substantive drawback to aggressive glycemic control
in ICUs is iatrogenic hypoglycemia. Several recent, large
multi-center randomized controlled trials (RCTs), includ-
ing the Glucontrol, VISEP, and NICE-SUGAR trials, have
been plagued with unacceptably high rates of hypoglyce-
mia in strict control arms [5-7]. This resulted in
p r e m a t u r es t u d yc l o s u r ei ns o m eo ft h e s et r i a l s .I nt h e
first pediatric ICU glycemic RCT, published in the Lancet
in February of 2009, the rate of hypoglycemia was 25% in
the strict control arm group [4]. Concerns regarding
hypoglycemia, substantiated by such trials, have caused
major medical oversight committees to recommend a
less strict approach to glycemic control [8-10]. Therapy-
induced hypoglycemia is the primary reason many pedia-
tric intensivists are reluctant to adopt standard glycemic
control approaches, likely due to the potential adverse
effects of low BG levels on the developing brain [11,12].
Both those who support or challenge glycemic control
efforts in critical care settings agree that glycemic man-
agement could be made significantly safer and more effi-
cient if there existed a means to more frequently and
reliably track patients’ glucose levels. Within the past
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been developed and approved to assist with outpatient
diabetes management. Due to concerns regarding altered
perfusion in critical illness, many have questioned the
accuracy of such devices in ICUs.
Materials and methods
Study design, patient enrollment, CGM placement and
monitoring
We conducted a single-center, prospective, non-blinded,
institutional review board-approved study. We enrolled 50
patients, ranging in age from 6 weeks to 16 years, admitted
to our mixed medical/surgical or cardiac ICU at Children’s
Healthcare of Atlanta at Egleston who required mechani-
cal ventilation and were at risk for developing critical ill-
ness hyperglycemia based on predefined risk factors.
Patients with known type I diabetes mellitus were not con-
sidered for enrollment. Following informed consent, an
area on the lower abdomen or thigh was cleaned with a
chlorhexidine gluconate/isopropyl alcohol solution and
the Medtronic Guardian®Real-Time Continuous Glucose
Monitoring System sensor (Medtronic, Northridge, CA,
USA) was placed via the manufacturer’s recommended
technique [13]. A wireless transmitter was attached to the
sensor and covered with a supplied transparent dressing
(Figure 1). Initial calibration of the CGM was performed
using arterial, venous, or capillary point-of-care (POC)
glucometry (iSTAT®, Abbot Laboratories, Princeton, NJ,
USA) at two hours and six hours after the sensor place-
ment. Subsequent calibrations occurred every 12 hours.
The CGM recorded a glucose reading every five minutes.
The sensor was replaced every five days during the study
unless contraindicated, and it was removed when partici-
pants no longer required mechanical ventilation and/or
vasoactive infusions. Although bedside nursing and physi-
cian teams were aware of enrollment, they did not assess
CGM readings and no changes in patient management
were based on values from the CGM. Audible alarms were
set for CGM values of ≤ 70 mg/dL (3.9 mmol/L) and ≥
200 mg/dL (11.1 mmol/L). With any alarm, the bedside
nurses were instructed to obtain a POC glucose measure-
ment, act accordingly to the POC value, and notify the
study staff.
Data acquisition and analysis
Demographic and clinical data were collected for all parti-
cipants. CGM values were compared to POC and labora-
tory BG measurements that occurred at or within five
minutes of CGM readings. A mixed model was performed
to assess the relationship between CGM and BG measure-
ments, as this accounts for the repeated measurements of
glucose levels. CGM versus BG agreement was assessed
using Clarke error grid analysis (Matlab® R2009A, Natick,
MA, USA) and Bland-Altman analysis. BG values used to
calibrate the CGM were not used for comparison, but all
other POC or laboratory BG measurements obtained dur-
ing the study period were compared to CGM values. This
included both BG measurements performed as part the
patient’s routine care and BG measurements obtained for
a high or low glucose alarm from the CGM.
Role of the funding source
This was an investigator-initiated study for which Med-
tronic® (Northridge, CA, USA) donated CGMs, but pro-
vided no other funding or support. Internal institution
funds were used to purchase the sensors for the GCM.
Results
Fifty patients were enrolled, and a total of 89 sensors
were used. There were 26 patients who had the sensor
r e m o v e di nl e s st h a nf i v ed a y s, because they no longer
met study criteria for critical illness hyperglycemia (that
is, they no longer required mechanical ventilation,
vasoactive medications, or continuous renal replacement
therapy). One patient did not have the device in place
long enough to record BG values, and two patients had
dysfunctional sensors with no data recorded. The two
patients with dysfunctional sensors were not signifi-
cantly different in degree of illness or condition than
the rest of the study patients. However, the sensors
used on these two patients came from the same box.
When a third patient started the study with a sensor
from this box, it also did not work. When a sensor
from a different box was used on this patient, it worked
very well. Therefore, we concluded that this box of sen-
sors was defective, and it was not used during the rest
of the study.
Of the 47 patients with accessible data, the mean age
was 4.3 years (range 6 weeks to 16 years-old) and 31
(66%) were male. Twenty-nine (62%) were medical
pediatric ICU patients, 8 (17%) were surgical pediatric
ICU patients (including general surgery, trauma surgery,
neurosurgery, and otolaryngology), and 10 (21%) were
cardiac surgery patients. Six (13%) had traumatic brain
injury or intracranial hemorrhage. All patients required
mechanical ventilation, and 30 (63.8%) required vaso-
pressor or inotropic infusions. Twenty (42.6%) devel-
oped critical illness hyperglycemia, defined as persistent
BG levels >140 mg/dL (7.7 mmol/L), and received insu-
lin via our published pediatric-specific hyperglycemia
protocol [14,15]. Six (12.8%) required continuous renal
replacement therapy (CRRT), and three (6%) developed
the need for veno-venous extracorporeal membrane
oxygenation (ECMO). Participants had indicators consis-
tent with high level of illness severity, including a mean
ICU length of stay (LOS) of 15 days. A total of 17 (36%)
patients had pediatric logistic organ dysfunction
(PELOD) scores ≥12 (Table 1).
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<40 mg/dL (2.2 mmol/L). Readings <40 mg/dL (2.2
mmol/L) from the CGM accounted for 0.2% of the total
64,315 CGM readings. All of the CGM readings of <40
mg/dL (2.2 mmol/L) took place in just five different
patients. When checked against BGs, these CGM read-
ings of <40 mg/dL (2.2 mmol/L) were shown to be fal-
sely low. The lowest BG drawn during an episode in
which the CGM reading was <40 mg/dL (2.2 mmol/L)
was 71 mg/dL (3.9 mmol/L). All of these episodes of fal-
sely low CGM readings corrected with sensor recalibra-
tion or replacement. There were no episodes of
hypoglycemia of <40 mg/dl (2.2 mmol/L) in any of the
POC or laboratory BGs during the entire study.
A total of 1,555 paired CGM and BG measurements
were analyzed using Clarke error grid and Bland-Altman
analysis (Figure 2). For the 1,555 paired CGM and BG
measurements, there is a statistically significant linear
relationship between CGM values and BG (P <.0001).
A one unit increase in CGM increases BG by an average
of .6537.
With Clarke analysis, readings in Zone A differ by
≤20%, whereas those in Zone B differ by >20% but do
not impact management. Readings in Zone A and B are
considered to have clinically acceptable correlation.
Zone C values would lead to therapeutic overcorrection
and Zone D readings would not trigger intervention,
although warranted. Zone E values would result in treat-
ment aggravating a hypo- or hyperglycemic state. With
Clarke error grid analysis of all patients, 74.6% of read-
ings were in Zone A and 23.3% of readings were in
Zone B, equating to 97.9% of all readings with clinically
acceptable correlation (Zone A + B). A total of 2.1% of
readings were in Zones C + D, and no readings were in
Zone E. Pearson’s correlation coefficient for all compari-
sons was 0.68. In Bland-Altman agreement analysis,
Figure 1 Application of the CGM sensor and transmitter to pediatric patients. The interstitial glucose sensor (solid arrow) was placed in the
subdermal, interstitial space on the abdomen (A) or upper thigh (B, C). The clam shell-appearing wireless transmitter (dotted line) was then
attached. In A, the sensor was placed on a 10 year-old female with H1N1 and respiratory failure who subsequently required veno-venous ECMO
(note the right femoral vein ECMO cannula and radial arterial catheter). Patient B depicts a three-year-old male trauma patient that had suffered
a gunshot wound. Patient C was a six-week-old male status-post traumatic brain injury. The supplied clear dressing facilitates site observation for
bleeding or reactions. Patients depicted in these photos were consented for photography.
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Page 4 of 10approximately 95% of all CGM values were +/- 58 mg/
dL (3.2 mmol/L) from the mean difference of -1.5 mg/
dL (0.08 mmol/L) between the CGM and BG values.
The mean absolute relative difference (MARD) between
CGM and BG values was 15.3%. The MARD gives the
average absolute difference between two methods of
measurement.
We compared BG and CGM glucose values in a variety
of subpopulations to investigate whether patient age,
diagnosis, support measures, or illness severity influenced
CGM function. We found a high correlation of glucose
values (that is, Clark Zone A + B >95%) in all age ranges,
including our youngest (<12 months old), and in all diag-
nostic categories. Sensor placement (thigh vs. abdomen)
did not impact reading accuracy. There was high correla-
tion in children who required support measures in addi-
tion to mechanical ventilation, including vasopressors,
inotropes, CRRT, and/or ECMO (Figures 2 and 3). Clini-
cally acceptable agreement was not obviously different in
those with low or high illness severity scores or according
to ICU LOS.
We also investigated whether CGM values correlated
with BG values in patients who developed critical illness
hyperglycemia and received insulin to maintain BG in the
80-140 mg/dL (4.4 to 7.7 mmol/L) range [5,12,14,15]. We
found a high correlation between BG and CGM readings
(98.2% in Zone A + B) in patients who required an insu-
lin infusion for critical illness hyperglycemia (Figure 2D).
No patient with CGM sensors in our study developed
a site infection, reaction, or bleeding. The insertion of
sensors was well tolerated with no obvious discomfort,
albeit all patients were receiving sedation and/or analge-
sia, because they were intubated and mechanically venti-
lated. There was no obvious interference with the CGM
from ICU monitors or electronic support devices. The
sensors and transmitters are not MRI compatible, and
for study subjects who required such imaging, the sen-
sors and transmitters were removed and then replaced
after the exam was complete.
Using software provided with the CGM, we overlaid
CGM and BG readings. Shown in Figure 4 are two
examples; one of a patient who developed critical illness
hyperglycemia and was managed with insulin and
another of a patient who developed hyperglycemia but
did not receive insulin due to age restrictions.
Discussion
Our study demonstrates that commercially available,
interstitial CGMs correlate closely with BG measure-
ments in critically ill children. Glycemic control in criti-
cally ill adults improves outcomes in a number of
studies from adult medical, surgical, and mixed ICUs,
and is recommended as standard practice by many med-
ical advisory committees [1,2,8,9,16]. A recent report by
Vlasselaers et al. also demonstrated clinical benefits of
strict glycemic control in a pediatric medical-surgical
ICU [4]. However, one issue that has plagued many gly-
cemic control trials in adults and children has been
unacceptably high rates of iatrogenic hypoglycemia in
strict control groups. Although the effect of hypoglyce-
mia on outcomes is unclear, these concerns have
resulted in a lack of adoption of routine glycemic man-
agement by some ICU practitioners (for example, those
in pediatric critical care).
Advocates and critics of glycemic control agree that a
reliable means to continuously sample and report glu-
cose levels will assist in understanding the effects of
ICU hyperglycemia and its management. Such technol-
o g yw o u l di m p r o v eb o t ht h ec o n s i s t e n c ya n ds a f e t yo f
glycemic control approaches. Notably, in discussing the
high rates of hypoglycemia despite outcome benefit in
their recently published RCT in pediatric critical care,
Vlasselaers et al. state that “...for future studies, an accu-
rate continuous blood glucose sensor for use in the
PICU...would be preferable tok e e pt h er i s ko fh y p o g l y -
caemia to a minimum [4].”
CGMs, which regularly assess interstitial glucose levels,
have been developed, approved, and marketed for outpati-
ent diabetes management. Although ICU practitioners
support the concept of utilizing such devices, many have
dismissed the potential use of such technology in critical
care settings. Their argument is that there may be an inac-
curacy of interstitial glucose values compared to blood
levels in patients with edema, poor perfusion, or in those
requiring vasoactive infusions. Despite these theoretical
drawbacks of CGM and interstitial glucose assessments,
little evidence exists to substantiate these concerns. There
is now a small cohort of limited studies of approximately
160 adult and pediatric ICU patients suggesting that there
is a reasonable correlation between CGM and BG mea-
surements [17-27].
We report one of the largest studies to date evaluating
a Food and Drug Administration (FDA) approved, com-
mercially available CGM in a critical care setting. We
assessed patients that our previous studies have proved
to be at increased risk for critical illness hyperglycemia
[12,14,15,28,29]. Currently, there is debate on which is
the gold standard blood supply (that is, arterial vs.
venous) to assess BG. In daily management, ICUs likely
use the most convenient and accessible vascular bed for
blood glucose determination and glycemic management,
including capillary sampling. Our study may provide gen-
eralizable and relevant data for practitioners and staff
who may use different sources for BG measurements.
In all patients and in subpopulation analysis based on
age, diagnosis, and ICU support measures, we found a
high correlation between CGM readings and standard
BG measurements per Clarke error grid and Bland-
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Page 5 of 10Altman analysis. Although some vasoactive medications
can result in peripheral vasoconstriction, this did not
affect the accuracy of interstitial readings in our study.
Correlation was also strong in those requiring CRRT
and/or ECMO, despite significant edema and vascular
leak syndrome in these patients. A 2005 report demon-
strated that a CGM device attached to an ECMO circuit
providing support for pediatric patients, could supply
reasonable glucose readings [30]. Our study appears to
be the first to evaluate CGMs on patients who required
ECMO, with the important note that sensors were placed
on patients before they were placed on ECMO.
Patients who were more severely ill according to tradi-
tional illness severity indicators (PELOD scores, ICU
lengths of stay) had excellent correlation between CGM
and standard readings. In fact, those with an ICU stay
Figure 2 Clarke error grid and Bland-Altman agreement analysis of paired BG readings. A total of 1,555 CGM values from 47 pediatric ICU
patients were compared for agreement with BG measurements (A). In Clarke plots (upper panel), the routine POC readings (X-axis) were
compared to corresponding CGM values (Y-axis). Readings in Zone A differ by ≤20%, whereas those in Zone B differ by >20% but do not impact
management. The Zone A + B composite is considered “clinically acceptable” correlation. Zone C values would lead to therapeutic
overcorrection and Zone D readings would not trigger intervention, although warranted. Zone E values would result in treatment aggravating a
hypo- or hyperglycemic state. In Bland-Altman analysis (bottom panel), the mean of the paired readings is on the X-axis, and the difference is on
the Y-axis. The broken line represents the cutoff of two standard deviations from the mean difference. In addition to the R
2, the solid line with
the indicated slope is shown and represents the correlation coefficient. Clarke and Bland-Altman plots are shown for patient subpopulations less
than one-year-old (B), those who received vasopressor or inotropic support (C), and those who developed critical illness hyperglycemia and
were managed with insulin using our protocol (D).
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Page 6 of 10of less than three days had the lowest Clark Zone A cor-
relation in our analysis. This may be due to the fact that
the precision of CGMs may improve with time after
insertion. It is interesting to note that one study that
found a poor correlation of CGMs in hospitalized
patients, sensors were in place for a maximum of three
days [27]. In addition, while some have questioned the
utility of such devices in very small pediatric patients,
we found excellent correlation in patients <12 months
of age. Also, we found excellent correlation in pediatric
ICU patients who were hyperglycemic and managed
with an insulin infusion.
A number of CGM devices have been approved for
outpatient use in children and adults [31-33]. FDA
approval applications have been supported by 90 to 99%
Clarke A + B correlation between CGM and standard
BG readings, and 1.6 to 10% of clinically inaccurate
r e a d i n g s( Z o n eC+D+E ) .S u ch applications cite stu-
dies evaluating approximately 20 to 137 patients [34-36].
Findings from our study of 47 participants, with Zone A
+ B of 97.9% and Zone B + C + D of 2.1%, are consis-
tent with criteria used in other venues to determine
acceptable accuracy. In addition, we found no untoward
effects of CGM use. Although critically ill patients often
have coagulopathies, we found no evidence of bleeding
with device use. Of note, sensors were not inserted
when a known severe coagulopathy was present. In
addition, we also found no site infections, reactions, or
significant discomfort noted with sensor placement or
use.
Our data provide some of the most robust evidence to
date that these devices can be used safely and provide
clinically meaningful information, even in the smallest
and most critically ill pediatric patients. In conjunction
Figure 3 Percentage of clinically acceptable paired glucose readings in patient subpopulations.P a t i e n t sw e r eg r o u p e db a s e do n
diagnosis (A), age or sensor site placement (B), support measures in addition to mechanical ventilation (C), development and/or treatment of
critical illness hyperglycemia (D), and severity of illness indicators (E). See Table 1 for corresponding subpopulation details. Clarke analysis was
conducted and shown as the percent of readings in Zone A and B. As is standard, we defined “clinically acceptable” correlations as the sum of
Zone A and B.
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Page 7 of 10with other CGM studies in ICU settings, it may be rea-
sonable to consider incorporating the use of such
devices into critical care practice, albeit with some
important limitations. We found that there is a signifi-
cant time and educational component needed to learn
to insert, calibrate and assess these devices. We also fre-
quently kept sensors in place for longer than the FDA-
recommended time. This sensor is currently approved
for 72 hours of use in the outpatient setting, and there
are no guidelines for their use in the ICU setting.
However, there are reports of these sensors being accu-
rate and safe for longer than the 72-hour period [37].
Medtronic has recently completed a study testing the
use of this sensor for six days in an inpatient setting,
and these results are pending [38]. Although our find-
ings demonstrate a strong correlation even with
extended use, we did not make any clinical management
decisions based on CGM readings. Only after further
study in clinical trials should such devices be used to
assist in titrating insulin during hyperglycemia
Figure 4 Temporal plot comparing CGM readings and BG values. With software provided with the CGM, CGM values and BG values were
plotted over time. CGM values (gray dots that at times morph into a line) are acquired approximately every five minutes, and BG values (black
squares) sporadically per regular care. We define persistent BG >140 mg/dL (7.7 mmol/L) as critical illness hyperglycemia, and have traditionally
managed those more than six months old with insulin infusions to a target BG of 80 to 140 mg/dL (4.4 to 7.7 mmol/L) (black dashed lines). The
top plot (A) represents data from a 13 year-old male with traumatic brain injury requiring mechanical ventilation and norepinephrine to
maintain his cerebral perfusion pressure. The arrows indicate when insulin was started and stopped per our protocol to manage his
hyperglycemia. The data in B is from a five-month-old male with Trisomy 21, RSV, pulmonary hypertension, and refractory hypoxemia requiring
high frequency oscillatory ventilation, inhaled nitric oxide, milrinone, and an epinephrine infusion. At the time of this study, this patient was
below our typical age threshold for protocolized hyperglycemic management, and he was not treated with insulin.
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Page 8 of 10management in critical care settings. Active diagnosis
and/or management of glucose disturbances in ICU set-
tings should only occur with time-tested BG
measurements.
The current state of evidence in this field may support
the use of such devices to trend patient BGs, and setting
high and low alarms to trigger standard BG assessment
may assist in improving the efficacy and safety of glyce-
mic control approaches. We experienced very few hypo-
glycemic episodes in this study, and thus the accuracy
of CGM in low-normal or hypoglycemic ranges is
unclear. Anecdotally, although our staff was essentially
blind to the readings of these monitors, there were
times when the “low” BG alarm was triggered, prompt-
ing our staff to perform a routine BG check. In one
notable case, a hyperglycemic patient treated with insu-
lin had her intravenous fluids switched from a high to
low dextrose-containing fluid without a change in insu-
lin dosing. The patient was not due to receive a routine
BG check, but after the CGM alarmed, a POC BG was
performed and confirmed a low reading. The IV fluid
discrepancy was noted, and the insulin infusion was
changed. As such, the most important utility of CGMs
at this time may be to trigger standard BG checks to
improve the safety of glycemic control.
Data from CGM devices will likely add to the under-
standing of glycemic control in the critically ill patient.
As shown in Figure 4, obtaining daily glucose trends via
CGM may help to identify the percent of time spent
outside of goal target ranges. Accurate, real-time assess-
ment of area-under-the-curve metrics can be obtained
from CGM devices. This may provide more meaningful
data compared to approaches currently used to define
and compare glycemic control.
Conclusions
Critically ill children encompass one of the widest spec-
trums of patients, in terms of size and condition, in any
ICU setting. The severity of illness and support mea-
sures of patients in this study were considerable. It may
be reasonable to consider that if CGMs function well in
our study population, they will likely function well in
most other ICU populations, whether pediatric, adult,
medical, or surgical. Yet, there will likely be scenarios
where CGM performance will be sub-standard, and
careful assessment during its use is required. Despite
the proven benefits of glycemic control in many critical
care settings, there are recognized risks of this approach
and more studies are needed to better define optimal
BG target ranges in the spectrum of ICU patients.
Our study adds to the body of evidence that refutes
the theoretical concerns regarding the use of CGM
devices in the ICU setting. There is no doubt that future
technologies will help advance the field of glycemic con-
trol in critical illness. The evidence may now support
t h eu s eo fc u r r e n t l ya v a i l a b l eC G M st oa s s i s tw i t ht h e
safety and efficacy of glycemic control in critical illness.
Further study and application for clinical approval of
CGM use in ICU settings should be paramount in the
international effort to better understand critical illness
hyperglycemia.
Key messages
￿ Hyperglycemia, hypoglycemia and glucose variabil-
ity are associated with poor outcomes in critical ill-
ness. However, recent studies on the control of
critical illness hyperglycemia have shown unaccepta-
bly high rates of iatrogenic hypoglycemia.
￿ This study demonstrates that interstitial CGMs
have a high degree of correlation with BG levels in a
wide variety of critically ill children.
￿ Our findings suggest that with further examination,
existing CGM technology may be a useful adjunct in
the detection and management of glucose disorders
in critically ill children.
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